Article Figures & Data
Figures
- Figure 1 Correlations between blood and CSF levels of neurofilament light chain (NfL)
Blood and CSF NfL concentrations were measured in the Lund (A) and London (B) cohorts. NfL measurements of matched CSF samples were available for 245 participants in the Lund cohort (147 Parkinson disease [PD], 28 multiple system atrophy [MSA], 15 progressive supranuclear palsy [PSP], 5 corticobasal syndrome [CBS], and 50 controls) and 97 participants in the London cohort (5 PD, 29 MSA, 26 PSP, 11 CBS, and 26 controls).
- Figure 2 Blood neurofilament light chain (NfL) in different diagnostic groups
Blood concentrations of NfL in the Lund (A), London (B), and early disease (C) cohorts; p values are from univariate general linear models adjusting for age and sex; *p < 0.05; **p < 0.01; ***p < 0.001. One progressive supranuclear palsy (PSP) case in the early disease cohort with NfL concentration of 134.3 pg/mL is not shown in C (but was included in all statistical analysis). CBS = corticobasal syndrome; MSA = multiple system atrophy; PD = Parkinson disease.
- Figure 3 Receiver operating characteristic (ROC) curves of blood neurofilament light chain (NfL)
ROC curves of blood NfL to distinguish Parkinson disease (PD) from atypical parkinsonian disorders (APD) (progressive supranuclear palsy [PSP], multiple system atrophy [MSA], and corticobasal degeneration [CBD]) in the Lund (A), London (B) and early disease (C) cohorts. The early disease cohort included 2 patient groups that were recruited in Göteborg and Umeå, respectively (e-Methods). ROC analysis produced similar results when diagnostic accuracy of blood NfL for differentiating PD from APD was assessed in Göteborg (area under the curve [AUC] 0.80) and Umeå (AUC = 0.81) patients separately.
Tables
Data Supplement
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Data Supplement - Microsoft Word file
Coinvestigators
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Coinvestigators - Microsoft Word file
Accompanying Editorial
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Accompanying Editorial - PDF
Argentine Translation
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Argentine Translation - PDF
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
